| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | E Jenny Heathcote | |
| Gideon M Hirschfield | |||
| Nadya Al-Harthi | |||
| P2860 | cites work | Primary biliary cirrhosis | Q21202919 |
| Ursodeoxycholic acid for primary biliary cirrhosis | Q24241945 | ||
| Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy | Q77058192 | ||
| Frequency and nature of the variant syndromes of autoimmune liver disease | Q77058224 | ||
| Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group | Q77807948 | ||
| Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial | Q77872001 | ||
| Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial | Q78039888 | ||
| Follow-up of children with autoimmune hepatitis treated with cyclosporine | Q79387112 | ||
| Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis | Q79745280 | ||
| Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse | Q79825440 | ||
| Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis | Q80032261 | ||
| The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: a cost-effectiveness analysis | Q80036427 | ||
| Consequences of treatment withdrawal in type 1 autoimmune hepatitis | Q80085817 | ||
| Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre | Q80087406 | ||
| Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease | Q80720176 | ||
| A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis | Q80883152 | ||
| Safety issues in the management of autoimmune hepatitis | Q81230534 | ||
| Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol | Q81641688 | ||
| Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly | Q82640069 | ||
| Controlled trial of prednisone and azathioprine in active chronic hepatitis | Q93735616 | ||
| Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis | Q93910045 | ||
| 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice | Q46939923 | ||
| Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series | Q46982272 | ||
| Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community | Q47404936 | ||
| Pregnancy in autoimmune hepatitis: outcome and risk factors | Q47858204 | ||
| Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery | Q47863504 | ||
| The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis | Q49110706 | ||
| The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid | Q50804108 | ||
| Prognosis of histological cirrhosis in type 1 autoimmune hepatitis | Q51035941 | ||
| Autoimmune diseases of the liver, autoimmune hepatitis and primary biliary cirrhosis: Unfinished business. | Q51733185 | ||
| Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. | Q53240102 | ||
| Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. | Q53271951 | ||
| Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis | Q24634370 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic Hepatitis | Q28248157 | ||
| Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis | Q28289028 | ||
| Management and outcome of pregnancy in autoimmune hepatitis | Q28345133 | ||
| Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? | Q30229501 | ||
| Autoimmune hepatitis, from mechanisms to therapy | Q33342074 | ||
| Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature | Q33371491 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis | Q33784003 | ||
| Wilson's disease with superimposed autoimmune features: report of two cases and review | Q33939750 | ||
| Hepatic and extrahepatic malignancies in primary sclerosing cholangitis | Q33957644 | ||
| Long-term follow-up of chronic active hepatitis of moderate severity | Q34474401 | ||
| Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared | Q34477263 | ||
| Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology | Q34494124 | ||
| Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. | Q34533943 | ||
| Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials | Q34550505 | ||
| Sclerosing cholangitis: a focus on secondary causes | Q34576071 | ||
| Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin | Q34598372 | ||
| The impact of ethnicity on the natural history of autoimmune hepatitis | Q34664271 | ||
| Immune-mediated drug-induced liver disease | Q34936720 | ||
| Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis | Q35621266 | ||
| Pancreatic pseudotumor with sclerosing pancreato-cholangitis: is this a systemic disease? | Q35716634 | ||
| An unusual form of autoimmune hepatitis in young Somalian men. | Q36075763 | ||
| Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. | Q36172804 | ||
| Primary sclerosing cholangitis: summary of a workshop | Q36581592 | ||
| Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic's HISORt criteria | Q36829566 | ||
| Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature | Q36835627 | ||
| Ursodeoxycholic acid for the treatment of primary biliary cirrhosis | Q36967686 | ||
| Optimising corticosteroid treatment for autoimmune pancreatitis | Q36999326 | ||
| The causes of primary biliary cirrhosis: Convenient and inconvenient truths | Q37039889 | ||
| Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging | Q37058826 | ||
| The challenges in primary sclerosing cholangitis--aetiopathogenesis, autoimmunity, management and malignancy | Q37096344 | ||
| Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents | Q37154336 | ||
| Overlap syndromes among autoimmune liver diseases | Q37182958 | ||
| Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? | Q37228810 | ||
| Preventative hepatology: minimising symptoms and optimising care. | Q37265614 | ||
| The natural history of small-duct primary sclerosing cholangitis | Q38457100 | ||
| The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis | Q40737262 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Transplantation trends in primary biliary cirrhosis. | Q42632785 | ||
| IgG4-related sclerosing disease | Q43072224 | ||
| Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid | Q43483632 | ||
| High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis | Q43618408 | ||
| A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis | Q43770466 | ||
| Autoimmune hepatitis in African Americans: presenting features and response to therapy | Q43844408 | ||
| Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients | Q43903202 | ||
| In primary sclerosing cholangitis, gallbladder polyps are frequently malignant | Q43996278 | ||
| Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal | Q44002045 | ||
| Diagnosis and treatment of autoimmune hepatitis | Q44080061 | ||
| Results of long-term ursodiol treatment for patients with primary biliary cirrhosis | Q44183498 | ||
| Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis | Q44387821 | ||
| Simplified criteria for the diagnosis of autoimmune hepatitis | Q44425899 | ||
| Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis | Q44487597 | ||
| Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis | Q44493764 | ||
| Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis | Q44517790 | ||
| Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients | Q44617739 | ||
| When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? | Q44797408 | ||
| A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results | Q44825279 | ||
| Induction of colitis in cftr-/- mice results in bile duct injury | Q44830095 | ||
| Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy | Q44902465 | ||
| Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis | Q44927729 | ||
| Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis | Q44930578 | ||
| Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy | Q45016057 | ||
| Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis | Q45045457 | ||
| Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis | Q45057464 | ||
| Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial | Q45163892 | ||
| Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis | Q45168074 | ||
| The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis | Q45247238 | ||
| Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial | Q45309693 | ||
| Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis | Q46408092 | ||
| Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic | Q46497062 | ||
| Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus | Q46584599 | ||
| The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study | Q46614923 | ||
| Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis | Q46688148 | ||
| Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease | Q46689681 | ||
| High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis | Q46705304 | ||
| Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis | Q46712369 | ||
| Mortality attributable to cholestatic liver disease in the United States. | Q46719878 | ||
| High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective | Q46722756 | ||
| Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis | Q46775425 | ||
| High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study | Q46802343 | ||
| Azithromycin may reduce cholestasis in primary sclerosing cholangitis: a case report and serendipitous observation | Q46819524 | ||
| Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. | Q53502601 | ||
| From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament. | Q53570884 | ||
| Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. | Q53888400 | ||
| Oral budesonide for treatment of autoimmune chronic active hepatitis | Q54020669 | ||
| Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. | Q54034536 | ||
| Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. | Q54118475 | ||
| Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. | Q55044287 | ||
| Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid | Q55174800 | ||
| Autoimmune Hepatitis | Q56210456 | ||
| New insights into autoimmune liver diseases | Q59384468 | ||
| Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: A nationwide study | Q59490154 | ||
| Risk factors for recurrence of primary sclerosing cholangitis of liver allograft | Q61796728 | ||
| Autoimmune pancreatitis | Q64044745 | ||
| Gallbladder disease in patients with primary sclerosing cholangitis. | Q64996440 | ||
| A prospective controlled trial of azathioprine in primary biliary cirrhosis | Q67479144 | ||
| A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results | Q67590480 | ||
| Severe chronic active liver disease. Prognostic significance of initial morphologic patterns | Q67707032 | ||
| Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial | Q68019501 | ||
| Ursodeoxycholic acid for primary sclerosing cholangitis | Q68095108 | ||
| Asymptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid | Q68842156 | ||
| Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis | Q69859277 | ||
| Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? | Q69896715 | ||
| Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution | Q70379977 | ||
| Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial | Q70542319 | ||
| Time course of histological progression in primary biliary cirrhosis | Q70869710 | ||
| Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis | Q71035932 | ||
| Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis | Q71039699 | ||
| Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis | Q71428816 | ||
| Azathioprine for Long-Term Maintenance of Remission in Autoimmune Hepatitis | Q72039839 | ||
| Azathioprine in primary biliary cirrhosis: a preliminary report of an international trial | Q72136152 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| A young woman with cirrhosis: autoimmune hepatitis vs. alpha 1-antitrypsin deficiency | Q72402227 | ||
| Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period | Q72503309 | ||
| Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology | Q72705542 | ||
| Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial | Q73026352 | ||
| Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group | Q73090826 | ||
| A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis | Q73118377 | ||
| Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis | Q73130778 | ||
| High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis | Q73144382 | ||
| Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid | Q73401694 | ||
| Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study | Q73568156 | ||
| High serum IgG4 concentrations in patients with sclerosing pancreatitis | Q73583110 | ||
| Duration of immunosuppressive therapy in autoimmune hepatitis | Q73700106 | ||
| Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis | Q73792757 | ||
| Reversibility of hepatic fibrosis in autoimmune hepatitis | Q73976726 | ||
| Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis | Q73979498 | ||
| A revised natural history model for primary sclerosing cholangitis | Q74042025 | ||
| Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients | Q74346215 | ||
| P433 | issue | 1 | |
| P921 | main subject | liver disease | Q929737 |
| P304 | page(s) | 11-28 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Therapeutic Advances in Gastroenterology | Q21042423 |
| P1476 | title | Current status of therapy in autoimmune liver disease | |
| P478 | volume | 2 |
| Q35078109 | Autoimmune hepatitis-primary biliary cirrhosis concurrent with biliary stricture after liver transplantation |
| Q35230369 | Autoimmune liver disease - are there spectra that we do not know? |
| Q38020714 | Diagnosis and treatment of autoimmune hepatitis |
| Q46891717 | Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration |
| Q34116241 | Low incidence of positive smooth muscle antibody and high incidence of isolated IgM elevation in Chinese patients with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome: a retrospective study |
Search more.